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Prevalence and patterns of multimorbidity
in Australian baby boomers: the Busselton
healthy ageing study
Michael L. Hunter1,2,3* , Matthew W. Knuiman2 , Bill (A.W.) Musk1,2 , Jennie Hui1,2,4 , Kevin Murray2 ,
John P. Beilby1,4 , David R. Hillman5 , Joseph Hung1,6 , Robert U. Newton7 , Romola S. Bucks8 ,
Leon Straker9 , John P. Walsh6,10 , Kun Zhu6,10 , David G. Bruce6 , Robert H. Eikelboom11,12,13 ,
Timothy M. E. Davis14 , David A. Mackey15 and Alan L. James1,5
Abstract
Background and objective: Chronic medical conditions accumulate within individuals with age. However,
knowledge concerning the trends, patterns and determinants of multimorbidity remains limited. This study assessed
the prevalence and patterns of multimorbidity using extensive individual phenotyping in a general population of
Australian middle-aged adults.
Methods: Participants (n = 5029, 55% female), born between 1946 and 1964 and attending the cross-sectional
phase of the Busselton Healthy Ageing Study (BHAS) between 2010 and 2015, were studied. Prevalence of 21
chronic conditions was estimated using clinical measurement, validated instrument scores and/or self-reported
doctor-diagnosis. Non-random patterns of multimorbidity were explored using observed/expected (O/E) prevalence
ratios and latent class analysis (LCA). Variables associated with numbers of conditions and class of multimorbidity
were investigated.
Results: The individual prevalence of 21 chronic conditions ranged from 2 to 54% and multimorbidity was
common with 73% of the cohort having 2 or more chronic conditions. (mean ± SD 2.75 ± 1.84, median = 2.00, range
0–13). The prevalence of multimorbidity increased with age, obesity, physical inactivity, tobacco smoking and family
history of asthma, diabetes, myocardial infarct or cancer. There were 13 pairs and 27 triplets of conditions identified
with a prevalence > 1.5% and O/E > 1.5. Of the triplets, arthritis (> 50%), bowel disease (> 33%) and depression-
anxiety (> 33%) were observed most commonly. LCA modelling identified 4 statistically and clinically distinct classes
of multimorbidity labelled as: 1) “Healthy” (70%) with average of 1.95 conditions; 2) “Respiratory and Atopy” (11%,
3.65 conditions); 3) “Non-cardiometabolic” (14%, 4.77 conditions), and 4) “Cardiometabolic” (5%, 6.32 conditions).
Predictors of multimorbidity class membership differed between classes and differed from predictors of number of
co-occurring conditions.
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Conclusion: Multimorbidity is common among middle-aged adults from a general population. Some conditions
associated with ageing such as arthritis, bowel disease and depression-anxiety co-occur in clinically distinct patterns
and at higher prevalence than expected by chance. These findings may inform further studies into shared
biological and environmental causes of co-occurring conditions of ageing. Recognition of distinct patterns of
multimorbidity may aid in a holistic approach to care management in individuals presenting with multiple chronic
conditions, while also guiding health resource allocation in ageing populations.
Keywords: Multimorbidity, Ageing, Co-morbidities, Middle-aged, Chronic disease
Background
In Australia and other developed countries, increasing
life expectancy and the transition of the Baby Boomer
generation (adults born 1946 to 1964) from middle into
older age has led to an increasing number of people with
multimorbidity, commonly defined as the presence of
two or more chronic, long-term health conditions [1].
Most studies report that multimorbidity is the norm in
the elderly and common in middle-age (45–64 years) [1–
3]. Multimorbidity is associated with greater risk of mor-
tality, poor quality of life, psychological stress, cognitive
decline, impaired functional capacity, greater use of
health and social support services and reduced work
productivity [3–10]. The growing prevalence of multi-
morbidity is also recognised in low- to middle income
countries where additional factors such as the presence
of communicable diseases, demographic transition and
socio-economic challenges contribute to the complexity
and burden of multimorbidity in these settings [11].
Individuals with multimorbidity have complex health-
care needs that may not be adequately addressed by
models of health care centred on managing and treating
single conditions. They are also at increased risk of ad-
verse drug effects from polypharmacy and potential
harm from conflicting treatment or lifestyle recommen-
dations [12]. Despite attempts to address these complex
needs in clinical guidelines [2, 13–15], knowledge con-
cerning the trends, patterns and determinants of multi-
morbidity remains sub-optimal. This has significant
implications for future healthcare service planning and
allocation of resources.
There have been several studies of the prevalence of
multimorbidity in primary care and general populations
including in Australia over the last decade [16]. These
have mostly involved cohorts, aged > 65+ years and have
used clinical administrative data, self-report or national
survey datasets to identify conditions and a variety of
measures to define multimorbidity [16–23]. The mea-
sures of multimorbidity in these studies are constrained
by the available data and vary widely in terms of the
number of considered conditions and their definitions
[24]. As a result, the prevalence and patterns of multi-
morbidity derived from different data sources are often
inconsistent, even when generated from the same
population sample [25, 26]. Notably, there have been few
community-based studies of multimorbidity, particularly
in middle-aged adults, that have used clinically-defined,
objective measures of chronic disease [14]. In their re-
view Fortin et al. concluded that, in general, multimor-
bidity increases with age, especially from the age of 40
years with a plateau around 70 years, if > 2 conditions
are used to define multimorbidity [14]. This plateau was
less evident if > 3 conditions was used to define
multimorbidity.
Certain conditions may be more likely to cluster than
others [27]. This may be the consequence of shared
pathophysiological pathways, in which the presence of
one condition increases the risk of another, or may re-
flect common environmental or biological risk factors.
In order to better understand the factors underlying pat-
terns of comorbidity and to thus inform healthcare plan-
ning, there have been recent calls for studies in general
population samples, assessing a wide range of conditions
characterised by objective clinical data including infor-
mation on symptoms, lifestyle behaviours and environ-
mental risk factors [28]. General population samples
matching these requirements, particularly in middle-age
when intervention for chronic conditions is likely to
have greatest impact in older age, are few.
The Busselton Healthy Ageing Study (BHAS) is one
such study where detailed measures of physical function,
cognition, well-being, quality of life, medical history and
biological samples have been collected enabling investi-
gation into specific interactions between disease pro-
cesses and symptoms within individuals [29]. The
objective of this analysis was to investigate the preva-
lence and patterns of multimorbidity using a range of
measures of chronic disease collected in the BHAS data-
set. We hypothesised that co-occurring conditions are
common in middle-aged adults, that there are identifi-
able non-random patterns of multimorbidity and that




A comprehensive, community-based health survey of
adults born 1946–1964 residing within the City of
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Busselton’s local government electoral boundary in
Western Australia was undertaken from May 2010 to
December 2015. All people listed on the compulsory
Western Australian Electoral Commission Electoral Roll
were invited to participate. Recruitment was via postal
invitation and by telephone where a contact number was
available. A total of 82% of those on the electoral register
could be contacted and confirmed eligible (non-institu-
tionalised and still living in the region) and 76% of those
contacted (5107) participated in the study. Ethical ap-
proval for this study was obtained from the Human Re-
search Ethics Committee of the University of Western
Australia (RA/4/1/2203). All study participants provided
written informed consent.
Participants completed a detailed questionnaire that
included items relating to medical and family history,
symptoms, physical activity and diet and nutrition (see
Supplementary File 1). They attended the survey centre
for up to 4 h of clinical assessments, which included:
spirometry, skin prick (atopy), audiometry, cardiovascu-
lar profiling (Ankle-Brachial Index, ABI) and electrocar-
diogram (ECG), bone densitometry and an in-home
overnight Apnealink™ sleep study. Participants also pro-
vided a fasting blood sample for blood glucose, haemo-
globin and white cell count, glycated haemoglobin
(HbA1c) and estimated glomerular filtration rate [30].
All clinical tests were conducted by accredited pathology
laboratories (PathWest, Busselton & Nedlands, Western
Australia). The complete BHAS protocol has been de-
scribed in detail previously [29].
Based on the participants’ responses and testing, 21
conditions were defined and included in this analysis
(Table 1). Six conditions were defined using only object-
ive measures or validated instrument scale score [31–
34]. Seven conditions were defined using a combination
of objective measures or validated instrument plus self-
reported doctor diagnosis and eight conditions were de-
fined only by self-reported doctor diagnosis which was a
“Yes” response to the question, “Has a Doctor ever diag-
nosed you with…?”. The list of conditions used in this
analysis ensured that the condition was prevalent and
chronic using the best available data from questionnaire
responses or clinical assessment.
Prevalence estimates and patterns of multimorbidity
The observed prevalence of each possible pair and triplet
combinations of concurrent conditions was determined
in the BHAS cohort. Pairs and triplets of conditions that
occurred more often than expected by chance (deter-
mined by a chi-square test for statistical independence
between conditions) were identified and the observed/
expected (O/E) prevalence ratio presented [18, 35]. The
expected chance prevalence under independence is
calculated as the product of the observed prevalences of
each condition in the pair or triplet.
Latent Class Analysis (LCA) was used to identify
groups (latent classes) of individuals with similar disease
profiles, that is, similar patterns of multi-morbidity. LCA
is a model-based statistical technique that is increasingly
recommended and used for this purpose [18, 21, 36]. In
our study the four class model was judged optimal and
we present the proportion of the population that is esti-
mated to be in each class, the estimated probabilities
that a person in each class has each of the 21 conditions
and the mean number of conditions for each class. The
multimorbidity profile of each class was used to inter-
pret and name the classes. Further details of the LCA
analysis are provided in Supplementary File 2.
Multivariable logistic and linear regression modelling
were used to identify the participant characteristics that
were related to latent class membership and overall
number of conditions respectively. Regression results are
presented as estimates with p-values. Statistical analyses
were performed using SAS® version 9.3 (and including
the Proc LCA extension).
Results
Complete data on 21 chronic conditions were available
for 5029 participants. The average age of the participants
was 54 years (range 45–69 years); 55% were female and
98% were Caucasian. Demographic details of the cohort
are provided in Supplementary Table S1. Comparison
with the Australian National Health Survey 2011 for
common risk factors for disease showed that the cohort
was similar to the Australian population on a number of
key health indicators including prevalence of obesity,
hypertension, hypercholesterolemia, and physical activity
rates. The prevalence of current tobacco smoking was
10% in the BHAS cohort, lower than the national aver-
age for this age group (15%).
Prevalence of individual conditions and number of
conditions per person
The prevalence and definitions of individual chronic con-
ditions are shown in Table 1. The number of co-occurring
conditions ranged from 0 to 13 (mean 2.75, SD = 1.84),
with 73% of participants having 2 or more conditions, 44%
of participants having one or two conditions and 49% hav-
ing three or more conditions. Only 7% of the cohort had
no conditions. The mean and number of conditions in-
creased with age, lower income and lower education level
in both men and women (Supplementary Table S1).
Relationship between number of conditions and
participant characteristics
Multiple linear regression modelling showed that female
gender; older age; increased waist circumference;
Hunter et al. BMC Public Health         (2021) 21:1539 Page 3 of 12
tobacco smoking; reduced physical activity; and family his-
tory of asthma, diabetes, myocardial infarct and cancer
were independently associated with increased number of
chronic conditions (Supplementary Table S2). When
standard drinks of alcohol per week and the dietary vari-
ables of meat meals per week, fish meals per week, vege-
table serves per day, fruit serves per day, were added to
the model they did not reach statistical significance (p =
0.28 for alcohol and p > 0.05 for dietary variables) and so
were not included in the final presented model.
Common pairs of conditions
There was a total of (21 × 20)/2 = 210 possible pairs of
conditions and all were observed with a prevalence that
varied from 0.02 to 13.42% (Table 2). There were 13
pairs of conditions with observed prevalence > 1.5% and
an O/E ratio > 1.5 (p < 0.0001 for all) (Table 2). Arthritis
and bowel disease was the most prevalent pair. Arthritis,
low back pain and depression–anxiety each featured in
at least three of these 13 pairs of conditions.
Common triplets of conditions
There was a total of (21 × 20 × 19)/6 = 1330 possible trip-
lets of conditions and 1261 were observed with preva-
lence from 0.02 to 4.97%. There were 27 triplets with a
prevalence > 1.5% and O/E ratio > 1.5 (p < 0.0001 for all)
(Supplementary Table S3). Bowel disease, arthritis and
atopy was the most prevalent triplet. Arthritis featured
in 16 of these 27 triplets of conditions and bowel disease
and depression–anxiety each featured in 11.
Patterns of multimorbidity – latent class analysis (LCA)
The morbidity patterns for the 4-class model are shown
in Table 3. The classes were defined as follows: Class 1
(70% of participants) “healthy” – below average preva-
lence for 20/21 conditions and average of 1.95 condi-
tions; Class 2 (11%) “respiratory and atopy” – well above




Atopy Positive (wheal > 3 mm) on skin prick tests for common allergens (dust-mites, grasses, moulds, cat hair, dog dander) 54.4
Arthritis Self-reported doctor-diagnosed 25.1
Bowel disease Self-reported doctor-diagnosed colonic polyps, Crohn’s disease, ulcerative colitis, irritable bowel syndrome or diverticular disease 23.3
Liver disease Self-reported doctor-diagnosed cirrhosis of the liver or ALT > 40 U/L in men or > 35 U/L in women 23.1
Depression/anxiety Current treatment or PHQ9 or GAD7 scores indicative of current depression or anxiety, respectively 20.5
Bronchitis Self-reported chronic cough or phlegm on most days for > 3 months each year 17.6
Eye condition Self-reported macular degeneration, glaucoma, cataract, non-diabetes related serious eye condition resulting in loss of vision 14.6
Asthma Self-reported doctor-diagnosed asthma 14.2
Heart disease Self-reported doctor-diagnosed angina, cardiac pacemaker, myocardial infarction, coronary angioplasty or stent, or bypass surgery
or Abnormal ECG
9.7
Thyroid disease Self-reported doctor-diagnosed 8.6
Low back pain Current self-reported chronic low back pain lasting > 3 months and Oswestry Disability Index > 12 8.5
Skin cancer Self-reported doctor-diagnosed 8.2
Obstructive Sleep
Apnoea
Apnoea hypopnea index > 19^ or, if not available, self-reported doctor-diagnosed 8.1
Hearing impairment Audiometry best ear 4-frequency average > 25 dB* or, if not available, hearing impairment affecting daily life frequently/constantly 7.1
Diabetes Self-reported doctor-diagnosed diabetes (not only during pregnancy) or fasting blood glucose > 7.0 mmol/L or glycosylated hae-





COPD Post-bronchodilator FEV1/FVC < 0.7 and FEV1% predicted < 80% or, if spirometry not available, self-reported doctor-diagnosed
COPD
5.7
Kidney disease Self-reported doctor-diagnosed kidney disease or estimated glomerular filtration rate < 60 ml/min 5.2
Osteoporosis DXA measured femur or AP spine T-score ≤ − 2.5^^ or, if not available, self-reported doctor-diagnosed 3.4
Stroke Self-reported doctor-diagnosed stroke, TIA or carotid surgery (endarterectomy or stent) 2.1
Peripheral artery
disease
Ankle brachial index < 0.9 for right or left side^^^ 1.9
Measured using ^Apnealink™ (Resmed), ^^Lunar Prodigy Pro Densitometer (GE), ^^^Vascular profiler VP1000™ (Omran), * Audiometry measured hearing loss of at least
25 dB (dB) (mean of thresholds at 500, 1000, 2000 and 4000 Hz)
Abbreviations:” ALT = Alanine transferase; PHQ9 = Patient Health Questionnaire-9; GAD7 = Generalised anxiety disorder – 7 item scale; COPD = Chronic obstructive
pulmonary Disease; FEV1 = Forced expired volume in 1 s; FVC = Forced vital capacity: DXA = Dual energy x-ray absorptiometry; AP = Anterior-posterior; TIA =
transient ischemic attack
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average prevalence of asthma, COPD and atopy and
below average prevalence of most other conditions, with
an overall average of 3.65 conditions; Class 3 (14%)
“multimorbid non-cardiometabolic”– well above average
prevalence of thyroid disease, bowel disease, osteopor-
osis, arthritis, low back pain, asthma, COPD, peripheral
arterial disease, hearing impairment, bronchitis and eye
conditions, with an overall average of 4.17 conditions;
Class 4 (5%) “multimorbid cardio-metabolic and other”-
well above average prevalence of heart disease, stroke,
peripheral arterial disease, diabetes, kidney disease, liver
disease, bowel disease, depression–anxiety, arthritis, low
back pain, sleep apnoea, asthma, bronchitis, chronic
hearing impairment and eye conditions, with an overall
average of 6.32 conditions.
Arthritis, low back pain, bowel disease, depression–
anxiety and bronchitis feature prominently in common
pairs and triplets of conditions that occur much more
often than expected by chance (all triplets O/E > 3.9)
and all of these conditions have high prevalence in
multi-morbid classes 3 and 4.
Asthma, COPD and atopy is a common triplet that
also occurs much more often than expected by chance
(O/E = 3.95) and these three conditions have high preva-
lence in “respiratory and atopy” class 2.
Characteristics of multimorbidity
Morbidity patterns versus number of conditions
There was a very strong association between having 0–2
conditions and being in ‘healthy’ class 1 (Supplementary
Table S4). Of the people with 0–2 conditions, 95% were
assigned to ‘healthy’ class 1 and 69% of people in class 1
had 0–2 conditions. Therefore, correlates and predictors
of being in ‘healthy’ class 1 and having 0–2 conditions
are essentially the same. People with 3–6 conditions
make up 46% of the total sample and were distributed
across all four classes. Although there was a strong asso-
ciation between having 7+ conditions and being in un-
healthy class 3 or 4 (94% of people with 7–13 conditions
were assigned to unhealthy classes 3 and 4), the morbid-
ity pattern was different for class 3 and class 4. Thus,
amongst people with three or more conditions, the num-
ber of conditions alone was not sufficient to discern the
pattern of multi-morbidity and correlates. Therefore pre-
dictors of being in class 3 and 4 may be quite different
and will not necessarily be the same as correlates of the
overall number of conditions.
Characteristics across assigned multimorbidity classes
Participants in the multi-morbid classes 3 and 4 were,
on average, 3 years older than those in classes 1 and 2
(Table 4). Classes 1 and 2 had approximately equal num-
bers of men and women whereas multi-morbid class 3
had a considerable majority of females and multi-morbid
class 4 a considerable majority of males. All characteris-
tics were significantly different across classes (all p <
0.001).
Relationship between membership of particular
multimorbidity class and participant characteristics
Multiple logistic regression of assigned membership of
each class (vs class 1) identified that individuals were
more likely to be classified as “respiratory and atopy”
(class 2) than ‘healthy’ (class 1) if they were female and
had family history of asthma (Table 5).
Individuals were more likely to be classified as “multi-
morbid non-cardio-metabolic” (class 3) than ‘healthy’
(class 1) if they were female, older, had a larger waist cir-
cumference, smoked, and had a family history of asthma,
myocardial infarction or cancer.
Individuals were more likely to be classified as “multi-
morbid cardio-metabolic and other” (class 4) than
‘healthy’ (class 1) if they were older, had a larger waist
circumference, smoked, did less physical activity, and
had a family history of asthma, diabetes and myocardial
infarction.
These results confirm that predictors of being in clas-
ses 2, 3 and 4 differ and are not the same as predictors
of the number of conditions.
Discussion
In this study, we have used an extensive range of clinic-
ally measured and self-reported chronic conditions and
two complementary analytical approaches to describe
the prevalence and patterns of multimorbidity in a com-
munity cohort of middle-aged adults. Our first approach,
using single disease counts of pairs and triplets of condi-
tions, identified that multimorbidity is prevalent and that
Table 2 All pairs of conditions with prevalence > 1.5% and
observed/expected ratio > 1.5 (and p < 0.0001)
Co-occurring pairs of conditions Prevalence (%) O/E
Asthma + COPD 2.41 2.95
Depression–anxiety + Low back pain 3.86 2.21
Arthritis + Low back pain 4.71 2.2
Bronchitis + COPD 1.89 1.86
Low back pain + Bronchitis 2.66 1.78
Diabetes + Eye condition 1.73 1.7
Diabetes + Liver disease 2.66 1.66
Depression–anxiety + OSA 2.64 1.6
Thyroid disease + Arthritis 3.46 1.59
Kidney disease + Depression anxiety 1.67 1.57
Liver disease + OSA 2.86 1.54
Bowel disease + Low back pain 3.02 1.53
Bowel disease + Arthritis 8.81 1.51
Note. Total prevalence of co-occurring conditions was 73%
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some combinations of conditions occur more frequently
than expected by chance. Our second approach, using
LCA, identified four unbiased classes of multimorbidity,
with differences in membership of each class charac-
terised by both higher probability of the number of
chronic conditions and a clinically-distinct groupings of
conditions. The predictors of chronic disease load (num-
ber of conditions) differed from those of patterns of
multimorbidity.
Using single disease counts, we showed that, although
the majority (73%) of adults in this cohort had two or
more chronic conditions, the overall prevalence of spe-
cific combinations of disease was relatively low. The
most prevalent pair (atopy and arthritis) had a preva-
lence of just over 13% and the most prevalent triplet
(arthritis, bowel disease and atopy) was observed in
under 5% of the cohort. By calculating O/E prevalence
ratios, we were able to identify combinations of disease
that occurred more frequently than expected by chance.
Some of the combinations identified in this cohort have
obvious pathological links or are well known to co-exist
clinically. Asthma and COPD either as a pair, or along
with atopy in a triplet, were combinations with high O/E
ratios and point towards well-documented inflammatory
links between allergy and respiratory function. Although
we mainly used spirometry to define COPD, the appear-
ance of this condition alongside asthma may point to-
wards overlap of symptoms or diagnostic mislabelling
and highlights the need for further research into how
these conditions might be better characterised [37].
Arthritis, bowel disease and low back pain were the
most common conditions appearing in highest ranked
O/E combinations alongside depression-anxiety. Arth-
ritis featured in 60% of the highest-ranking triplets of
conditions and bowel disease and depression-anxiety
featured in 40%. Depression-anxiety featured in over
Table 3 Morbidity characteristics of individuals assigned to Classes of multimorbidity
ALL CLASS 1 CLASS 2 CLASS 3 CLASS 4












3541 (70.4%) 529 (10.5%) 691 (13.7%) 268 (5.3%)
Mean number of
conditions











Atopy 54.4 52.3 82.0 40.8 62.7
Arthritis 25.1 13.3 24.6 77.1 48.1
Bowel disease 23.3 16.5 21.9 54.1 35.4
Liver disease 23.1 21.9 23.3 15.8 57.5
Depression/anxiety 20.5 13.3 14.7 54.6 38.4
Bronchitis 17.6 11.8 20.6 37.8 36.9
Eye condition 14.6 10.8 11.9 30.4 29.1
Asthma 14.2 0.1 99.1 14.5 32.5
Heart disease 9.7 7.7 9.1 7.4 44.0
Thyroid disease 8.6 5.2 7.6 25.8 12.3
Low back pain 8.5 1.6 4.7 37.5 32.5
Skin cancer 8.2 8.7 4.7 8.7 6.3
OSA 8.1 5.8 2.5 12.4 37.3
Hearing impairment 7.1 6.0 3.6 11.6 16.4
Diabetes 7.0 4.2 0.0 4.3 64.6
Non skin cancer 6.7 5.0 6.2 14.2 10.8
COPD 5.7 2.7 19.3 8.4 13.1
Kidney disease 5.2 3.4 2.6 10.0 20.9
Osteoporosis 3.4 2.7 4.2 7.7 0.4
Stroke 2.1 0.9 0.8 2.5 20.1
Peripheral artery
disease
1.9 1.2 1.5 1.6 12.3
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one-third of all triplets identified and was highly preva-
lent among LCA Class 4 with the highest condition load.
Depression is a common feature of multimorbidity [38]
and has been associated with a range of chronic condi-
tions including cardiac disease, stroke, loss of hearing,
loss of vision, and chronic lung diseases such as asthma
and COPD [39, 40]. In our study, depression-anxiety
often featured in combination with arthritis, back pain
and bowel disease. Previous studies have shown high
prevalence of depression and anxiety in inflammatory
bowel disorders such as ulcerative colitis and Crohn’s
disease [41, 42]. Depression is also a common comorbid
feature in different arthritis subtypes [43] and can
worsen both the severity of and disability caused by
chronic low back pain [44]. As depression is a treatable
illness, a rational approach may be to screen for and
treat comorbid depression in patients presenting with
these patterns of multimorbidity.
Other combinations of disease identified in our study
may point towards shared aetiologies. The high co-
occurrence of arthritis with bowel disease has been de-
scribed in previous studies and was a common combin-
ation identified in both our disease counts (7/27 triplets)
and occurred in high prevalence in LCA Classes 3 and 4
[45, 46]. Previous studies have suggested changes in gut
bacteria as potentially implicated in the development of
joint inflammation, or alternatively recruitment of gut
lymphocytes or activated macrophages in joint inflam-
mation [47].
Common risk factors such as obesity, tobacco smoking,
physical inactivity, and family history may underlie some
of these patterns, yet predictors of latent class member-
ship showed distinct differences. Our analysis of the life-
style factors underlying class membership or the number
of chronic conditions did not find alcohol consumption or
diet variables (data not shown) to be significant variables.
LCA patterns
The largest disease burden was evident in Classes 3 and
4, which together comprised around 20% of the cohort.
Table 4 Comparison of participant characteristics across assigned multimorbidity classes












(n = 3541) (n = 529) (n = 691) (n = 268) P -
value*
Age (mean years) 58.0 57.5 57.1 60.2 61.0 <
0.001
Sex (Female, %) 54.8 52 61 73 36 <
0.001
Waist circumference (mean cm) 92.2 91.0 90.8 93.3 108.6 <
0.001
Tobacco smoking:
Never (%) 47 48 49 43 35
Former (%) 43 43 43 41 51
Current < 15 cigarettes per day (%) 4 4 3 7 4 <
0.001
Current 15 cigarettes per day (%) 6 5 5 9 9
Moderate/vigorous physical activity
(mean total hours per week)
9.5 10.1 9.0 7.8 7.4 <
0.001
Alcohol consumption (mean total
glasses per week)
11.5 11.9 10.9 9.7 12.1 0.001
First degree relatives# with:
Asthma 0.34 0.29 0.59 0.37 0.39 <
0.001
Diabetes 0.37 0.34 0.36 0.42 0.61 <
0.001
Myocardial infarct 0.5 0.47 0.44 0.62 0.69 <
0.001
Cancer (any type) 0.86 0.82 0.84 1.03 0.91 <
0.001
* P-value from chi-square test for categorical characteristic or from ANOVA for quantitative characteristic
# Condition reported in biological mother, father, brother(s), sister(s) – mean number
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Individuals assigned to Class 3 multi-morbid non-
cardiometabolic had an average of over 4 chronic condi-
tions and showed a higher probability of musculoskeletal
conditions (arthritis, low back pain and osteoporosis);
conditions resulting in sensory deficits (hearing impair-
ment and eye conditions); and non-cardiovascular condi-
tions including bowel, thyroid and kidney diseases.
Individuals in this category were more likely to be fe-
male (73%) and older than those in classes 1 and 2.
While only 5% of the cohort was assigned to Class 4, this
class was 64% male and had the highest disease load
with an average of six co-occurring chronic conditions.
Cardiometabolic conditions including heart disease, dia-
betes, stroke, and peripheral artery disease along with
liver disease and sleep apnoea were highly prevalent in
this group. Individuals in Class 4 were much more likely
to be male, older and obese.
Similar to the findings for common pairs and triplets,
Class 2 was characterised by above-average prevalence
of respiratory and allergy conditions but did not signifi-
cantly differ from Class 1 (relatively healthy) in terms of
age, obesity or smoking status. This is interesting be-
cause this class shows a distinct clustering of multimor-
bidity that was not associated with increased age (the
average age was lower in this group compared with Clas-
ses 3 and 4) or with behavioural risk factors related to
poor lung function, such as smoking and excess abdom-
inal fat (compared with Class 1). Family history of
asthma was a significant predictor of membership of this
group, perhaps highlighting a strong genetic and early
life component underlying this pattern of
multimorbidity.
Comparing our findings with previous studies that
identify multimorbidity patterns is difficult due to the
heterogeneity in the populations and age-ranges sam-
pled, disease type and number of conditions included, as
well as variation in data sources and analytical methods.
Nonetheless a systematic review of 14 studies on non-
random patterns of multimorbidity provides support for
three broad categories consisting of cardiovascular and
metabolic diseases, musculoskeletal disorders and men-
tal health disorders [27]. Using disease counts, similar
patterns have been described in Australian samples. Britt
et al. found that arthritis, chronic back pain and
depression-anxiety conditions were the most prevalent
combinations of conditions, along with vascular disease,
in older primary-care patients [20]. Holden et al. used
exploratory factor analysis to describe patterns and iden-
tified a dominant group with arthritis and irritable bowel
disease [17].
Relatively few published studies have employed LCA
to describe multimorbidity classes in general population
samples. An Australian study of over 4500 adults with
mean age of 69 years included 11 self-reported disease
conditions resulting in four multimorbidity LCA classes
[18]. Similar to our findings, the majority of the study
sample (> 55%) were assigned to a minimally diseased
(‘healthy’) group. The remainder were assigned to groups
characterised by dominant presence of either: arthritis
and asthma and depression–anxiety; high blood pres-
sure and diabetes, or; cancer and heart disease and
stroke. The clustering of conditions in that study was
largely consistent across the multiple analytical tech-
niques employed, which included pair/triplet disease
Table 5 Relationship between membership of particular multi-morbidity class and participant characteristics
Comparison Class 2 vs Class 1 Class 3 vs Class 1 Class 4 vs Class 1
Characteristic Estimated odds ratio P Value Estimated odds ratio P Value Estimated odds ratio P Value
Sex (female vs male) 1.409 0.0023 3.227 < 0.0001 1.076 0.6511
Age (per year) 0.996 0.6518 1.089 < 0.0001 1.113 < 0.0001
Waist circumference (per cm) 1.006 0.1275 1.026 < 0.0001 1.097 < 0.0001
Tobacco smoking
Current 15 cigs/day vs never 0.982 0.9370 3.382 < 0.0001 3.216 < 0.0001
Current < 15 cigs/day vs never 0.816 0.4383 2.527 < 0.0001 1.915 0.0737
Former smoker vs Never smoked 0.959 0.6769 1.084 0.3951 1.228 0.1869
Weekly moderate/vigorous physical
activity (per hr)
0.995 0.2739 0.993 0.0703 0.986 0.0251
First degree relative with:
Asthma 1.834 <.0001 1.189 0.0139 1.335 0.0080
Diabetes 0.981 0.8029 1.076 0.2792 1.437 0.0001
Myocardial infarct 0.882 0955 1.141 0.0293 1.291 0.0065
Cancer (any) 0.999 0.9790 1.237 < 0.0001 1.061 0.4747
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combinations and cluster analyses. While we identified
broadly similar combinations of conditions and clusters
in our study sample, it is likely that inclusion of more
conditions in our analyses resulted in a distinct grouping
of cardio-metabolic conditions that included diabetes,
heart disease and stroke into a single class (Class 4). A
study using 15 self-reported conditions in over 160,000
Danish citizens with mean age 47 years, identified seven
classes of multimorbidity, three of which were similar to
those identified in our analyses [21]. These include a dis-
tinct “musculoskeletal class” characterised by high prob-
ability of arthritis, osteoporosis and back injuries; a
“complex cardio-metabolic disorders” class with high
probability of diabetes, heart disease and stroke, similar
to our Class 4; and a third class termed “asthma–al-
lergy”, similar to our Class 2 but which did not include
COPD.
A US study of over 14,000 adults aged over 65
years used 13 self-reported conditions identified six
latent multimorbidity classes [36]. Only one-third
were assigned to a “Minimal disease” group and the
remainder spread between groups characterised by
vascular, non-vascular, cardio-stroke-cancer or
neurological disease, and a ‘Very sick’ group with
above average prevalence of all conditions. These
findings differ from our study in that we found dis-
tinct differences between predictors of class mem-
bership and number of diseases, and that the
majority of our sample (70%) fell within a relatively
healthy (minimal disease) group, the latter of which
may be explained by the overall younger age of our
cohort.
Comparing the patterns of multimorbidity identified
in our study and others conducted in high income
countries, with patterns identified in low-middle in-
come countries is difficult given the different nature
of disease burden and the limited availability of stud-
ies. Nonetheless a recent LCA analysis in cohorts
from both low and high income countries identified
three classes, two of which labelled “cardio-metabolic”
and “healthy” were similar to those found in our
study and others [27, 48]. However the proportion of
individuals in each of the multimorbidity classes dif-
fered across regions highlighting the difficulties in
comparing multimorbidity burden and patterns across
different socio-economic and epidemiological settings.
Strengths
The strengths of our study include a high participation
and completion rate in a moderately large community-
dwelling cohort, assessed at an age where chronic dis-
ease load often begins to manifest. By using a large num-
ber of conditions (over 50% of which were defined by
physical or biochemical clinical measure or validated
instrument score) and including those conditions that
are current and chronic (long-lasting symptoms and
likely to impact on daily activities) we have captured a
comprehensive range of conditions of ageing that have
not been able to be included in previous studies of
multimorbidity.
Limitations
Our sample was drawn from a regional urban commu-
nity; however the cohort was similar on a number of key
health indicators to the general Australian population.
Current medication use, although available, was not in-
cluded in the definition or criteria for any of the condi-
tions so as to avoid potential misclassification errors that
may arise from off-label prescribing or under-reporting.
Without an objective clinical marker for arthritis (similar
to other studies), we have relied on self-reported doctor
diagnosis, but we used validated instrument scores to
capture musculoskeletal conditions including low back
pain and a wide range of gastrointestinal disorders in
our definition of bowel disease, some of which have not
often been included in previous studies of multimorbid-
ity patterns [32].
When defining multimorbidity, “health conditions”
may include diseases, risk factors or symptoms. The
present analysis has included predominantly conditions
that are diseases or symptoms. We therefore did not in-
clude conditions such as obesity or hypertension. While
hypertension can be considered a cardiovascular condi-
tion, it was not included in this analysis because of its
very strong risk factor association with stroke, heart dis-
ease, kidney disease and diabetes and is thus a somewhat
redundant aspect of the cardio-metabolic profile and
patterns identified. Decisions on what to include when
defining multimorbidity depend on the purpose of the
definition, e.g. assessing effects on perceived future risk,
or effects on current function and disability, or effects
on health care costs [48]. The present study aimed at
examining how diseases and symptoms co-occurred and
might be predicted.
Conclusion
Our findings indicate that multimorbidity is common
among middle-aged adults and some conditions co-
occur in clinically distinct patterns and at higher preva-
lence than expected by chance. The identification of
non-random patterns of multimorbidity may guide fur-
ther mechanistic studies into shared biological and en-
vironmental causes of co-occurring conditions of ageing.
As the Busselton Healthy Ageing Study is designed as a
longitudinal survey, the conduct of future phases and
analyses will track and relate patterns of multimorbidity
to prevalent and incident cognitive and physical disabil-
ity and use of healthcare resources. The findings of these
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studies will be of major importance to the primary ra-
ther than specialist care management of older individ-
uals in whom multiple physical and mental health
conditions require a holistic view.
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